CAP final rule expected next month with revised drug list

Article Overview

This article covers an update on the Centers for Medicare & Medicaid Services’ planned final rule for the Medicare Competitive Acquisition Program (CAP), including anticipated changes to the list of drugs available through vendors and the program’s payment and participation framework. It is relevant to physicians, practice administrators, and medical billing/coding professionals monitoring Medicare Part B drug acquisition policy, vendor operations, and related program implementation issues. The article discusses the broader regulatory context, vendor concerns, and how CMS is trying to support participation in the program.